ReviewBlood science (Baltimore, Md.)2026
Platelet subpopulations and contribution to hemostasis.
Review in Blood science (Baltimore, Md.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Platelets are traditionally considered a homogeneous population of anucleate cells derived from megakaryocytes, primarily responsible for hemostasis and thrombus formation. However, advances in platelet phenotyping and functional assays have revealed substantial heterogeneity within the platelet population, identifying distinct subpopulations with specialized functions. These subpopulations, including reticulated, procoagulant, aggregatory, and coated platelets, are characterized by distinct molecular signatures, activation thresholds, and functional roles that differentially influence thrombin generation, clot stability, and vascular integrity. Their variable reactivity and interactions with leukocytes and coagulation pathways position them as critical mediators of thromboinflammation. These subpopulations also display varied responses to commonly used antiplatelet medications. Reticulated platelets (RPs), for instance, are younger and more reactive, and have been associated with relative resistance to aspirin and P2Y12 inhibitors. Despite significant advances, the precise contributions of platelet subpopulations to hemostasis and disease progression remain poorly understood, largely due to the lack of standardized markers and methodological variability across studies. This review critically summarizes current insights into platelet heterogeneity, emphasizing the functional relevance of specific subpopulations and their pharmacologic profiles while addressing existing limitations and unresolved controversies. Furthermore, it discusses emerging research strategies aimed at refining platelet classification and explores how a deeper understanding of platelet heterogeneity may facilitate the development of precision-based diagnostic tools and targeted antiplatelet therapies. Such approaches may ultimately improve risk stratification and therapeutic outcomes in thrombotic and inflammatory disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.